Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Western blot seroindeterminate individuals for human T-lymphotropic virus I/II (HTLV-I/II) in Fortaleza (Brazil): a serological and molecular diagnostic and epidemiological approach.

Santos Tde J, Costa CM, Goubau P, Vandamme AM, Desmyter J, Van Doren S, Mota RM, de Castro Costa FB, Oliveira AC, Barreto V, Gomes AF, Carneiro-Proietti AB, de Bruin VM, de Sousa FC, Oriá RB.

Braz J Infect Dis. 2003 Jun;7(3):202-9.

2.

A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure.

Van Vaerenbergh K, De Geest S, Derdelinckx I, Bobbaers H, Carbonez A, Deschamps A, De Graeve V, De Saar V, Ceunen H, De Smet K, Maes B, Peetermans W, Schrooten Y, Desmyter J, De Clercq E, Van Ranst M, Van Wijngaerden E, Vandamme AM.

Antivir Chem Chemother. 2002 Jul;13(4):231-40.

PMID:
12495211
3.

Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients.

Van Vaerenbergh K, Harrer T, Schmit JC, Carbonez A, Fontaine E, Kurowski M, Grünke M, Löw P, Rascu A, Schmidt B, Schmitt M, Thoelen I, Walter H, Van Laethem K, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM.

AIDS Res Hum Retroviruses. 2002 Apr 10;18(6):419-26.

PMID:
11958685
4.

Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium.

Van Vaerenbergh K, Debaisieux L, De Cabooter N, Declercq C, Desmet K, Fransen K, Maes B, Marissens D, Miller K, Muyldermans G, Sprecher S, Stuyver L, Vaira D, Verhofstede C, Zissis G, Van Ranst M, De Clercq E, Desmyter J, Vandamme AM.

Antivir Ther. 2001 Mar;6(1):63-70.

PMID:
11417763
5.
6.

Postscript relating to new allegations made by Edward Hooper at The Royal Society Discussion Meeting on 11 September 2000.

Plotkin SA, Teuwen DE, Prinzie A, Desmyter J.

Philos Trans R Soc Lond B Biol Sci. 2001 Jun 29;356(1410):825-9.

7.

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.

Van Laethem K, Witvrouw M, Pannecouque C, Van Remoortel B, Schmit JC, Esnouf R, Kleim JP, Balzarini J, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 2001 Mar 30;15(5):553-61.

PMID:
11316991
8.

Recent increase in diagnoses of HIV infections based on surveillance system data in Belgium.

Sasse A, Liesnard C, van der Groen G, Burtonboy G, Plum J, Sondag-Thull D, Sprecher S, Van Ranst M, Zissis G, Desmyter J.

AIDS. 2000 Dec 1;14(17):2798-800. No abstract available.

PMID:
11125905
9.

From polio to AIDS, 1950-2005.

Desmyter J.

Acta Clin Belg. 2000 Jul-Aug;55(4):197-8. No abstract available.

PMID:
11036676
10.

Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.

Van Laethem K, Schmit JC, Pelemans H, Balzarini J, Witvrouw M, Pérez-Pérez MJ, Camarasa MJ, Esnouf RM, Aquaro S, Cenci A, Perno CF, Hermans P, Sprecher S, Ruiz L, Clotet B, Van Wijngaerden E, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM.

AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):825-33.

PMID:
10875608
11.

In vitro evaluation of the effect of temporary removal of HIV drug pressure.

Witvrouw M, Pannecouque C, Desmyter J, De Clercq E, Andries K.

Antiviral Res. 2000 Jun;46(3):215-21.

PMID:
10867159
12.

Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations.

Van Laethem K, Van Vaerenbergh K, Schmit JC, Sprecher S, Hermans P, De Vroey V, Schuurman R, Harrer T, Witvrouw M, Van Wijngaerden E, Stuyver L, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM.

J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):107-18.

PMID:
10843523
13.

Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.

Van Vaerenbergh K, Van Laethem K, Van Wijngaerden E, Schmit JC, Schneider F, Ruiz L, Clotet B, Verhofstede C, Van Wanzeele F, Muyldermans G, Simons P, Stuyver L, Hermans P, Evans C, De Clercq E, Desmyter J, Vandamme AM.

AIDS Res Hum Retroviruses. 2000 Apr 10;16(6):529-37.

PMID:
10777143
14.

Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir.

Van Laethem K, Witvrouw M, Balzarini J, Schmit JC, Sprecher S, Hermans P, Leal M, Harrer T, Ruiz L, Clotet B, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 2000 Mar 10;14(4):469-71. No abstract available.

PMID:
10770556
15.
16.

Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs.

Vandamme AM, Witvrouw M, Pannecouque C, Balzarini J, Van Laethem K, Schmit JC, Desmyter J, De Clercq E.

Methods Mol Med. 2000;24:223-58. doi: 10.1385/1-59259-245-7:223.

PMID:
21331913
17.

High prevalence of GB virus C/hepatitis G virus in Kinshasa, Democratic Republic of Congo: a phylogenetic analysis.

Liu HF, Muyembe-Tamfum JJ, Dahan K, Desmyter J, Goubau P.

J Med Virol. 2000 Feb;60(2):159-65.

PMID:
10596015
18.

Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.

Cabrera C, Witvrouw M, Gutiérrez A, Clotet B, Kuipers ME, Swart PJ, Meijer DK, Desmyter J, De Clercq E, Esté JA.

AIDS Res Hum Retroviruses. 1999 Nov 20;15(17):1535-43.

PMID:
10580404
19.

Different population dynamics of human T cell lymphotropic virus type II in intravenous drug users compared with endemically infected tribes.

Salemi M, Lewis M, Egan JF, Hall WW, Desmyter J, Vandamme AM.

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13253-8.

20.

The discovery of two new divergent STLVs has implications for the evolution and epidemiology of HTLVs.

Van Brussel M, Salemi M, Liu HF, Goubau P, Desmyter J, Vandamme AM.

Rev Med Virol. 1999 Jul;9(3):155-70. Review.

PMID:
10479777
21.

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.

Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 1999 Aug 20;13(12):1477-83.

PMID:
10465070
22.
23.

The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy.

Salemi M, Vandamme AM, Desmyter J, Casoli C, Bertazzoni U.

Gene. 1999 Jun 24;234(1):11-21. Review.

PMID:
10393234
24.

Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood.

Vandamme AM, Van Laethem K, Schmit JC, Van Wijngaerden E, Reynders M, Debyser Z, Witvrouw M, Van Ranst M, De Clercq E, Desmyter J.

Eur J Clin Invest. 1999 May;29(5):445-52.

PMID:
10354202
25.

Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey.

Hoppenbrouwers K, Kanra G, Roelants M, Ceyhan M, Vandermeulen C, Yurdakök K, Silier T, Dupuy M, Pehlivan T, Ozmert E, Desmyter J.

Vaccine. 1999 Feb 26;17(7-8):875-86.

PMID:
10067694
26.

The simian origins of the pathogenic human T-cell lymphotropic virus type I.

Vandamme AM, Salemi M, Desmyter J.

Trends Microbiol. 1998 Dec;6(12):477-83. Review.

PMID:
10036726
27.

Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12.

Witvrouw M, Daelemans D, Pannecouque C, Neyts J, Andrei G, Snoeck R, Vandamme AM, Balzarini J, Desmyter J, Baba M, De Clercq E.

Antivir Chem Chemother. 1998 Sep;9(5):403-11.

PMID:
9875393
28.

Evidence for a post-Columbian introduction of human T-cell lymphotropic virus [type I] [corrected] in Latin America.

Van Dooren S, Gotuzzo E, Salemi M, Watts D, Audenaert E, Duwe S, Ellerbrok H, Grassmann R, Hagelberg E, Desmyter J, Vandamme AM.

J Gen Virol. 1998 Nov;79 ( Pt 11):2695-708. Erratum in: J Gen Virol 1999 Apr;80(Pt 4):1087.

PMID:
9820145
29.

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.

Schmit JC, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sönnerborg A, Leal M, Harrer T, Clotet B, Arendt V, Lissen E, Witvrouw M, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 1998 Oct 22;12(15):2007-15.

PMID:
9814869
30.

Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.

Schmit JC, Ruiz L, Stuyver L, Van Laethem K, Vanderlinden I, Puig T, Rossau R, Desmyter J, De Clercq E, Clotet B, Vandamme AM.

J Virol Methods. 1998 Jul;73(1):77-82.

PMID:
9705178
32.

Two new human T-lymphotropic virus type I phylogenetic subtypes in seroindeterminates, a Mbuti pygmy and a Gabonese, have closest relatives among African STLV-I strains.

Salemi M, Van Dooren S, Audenaert E, Delaporte E, Goubau P, Desmyter J, Vandamme AM.

Virology. 1998 Jul 5;246(2):277-87.

33.

Evolutionary rate and genetic heterogeneity of human T-cell lymphotropic virus type II (HTLV-II) using isolates from European injecting drug users.

Salemi M, Vandamme AM, Gradozzi C, Van Laethem K, Cattaneo E, Taylor G, Casoli C, Goubau P, Desmyter J, Bertazzoni U.

J Mol Evol. 1998 May;46(5):602-11.

PMID:
9545470
34.

Vaginitis.

Donders GG, Desmyter J, Vereecken A.

N Engl J Med. 1998 May 21;338(21):1548; author reply 1549. No abstract available.

35.

Anti-hepatitis G E2 antibody detection and its relation to serum HGV-RNA in patients with clotting disorders: high prevalence of HGV infection and spontaneous remission.

Sheng L, Soumillion A, Peerlinck K, Verslype C, Schelstraete R, Gyselinck F, Emonds MP, Hess G, Vermylen J, Desmyter J, Yap SH.

Thromb Haemost. 1998 Apr;79(4):752-5.

PMID:
9569187
36.

The simian T-lymphotropic virus STLV-PP1664 from Pan paniscus is distinctly related to HTLV-2 but differs in genomic organization.

Van Brussel M, Salemi M, Liu HF, Gabriëls J, Goubau P, Desmyter J, Vandamme AM.

Virology. 1998 Apr 10;243(2):366-79.

37.

Diagnosis of human immunodeficiency virus infection by a polymerase chain reaction assay evaluated in patients harbouring strains of diverse geographical origin.

Van Laethem K, Beuselinck K, Van Dooren S, De Clercq E, Desmyter J, Vandamme AM.

J Virol Methods. 1998 Feb;70(2):153-66.

PMID:
9562409
38.

African origin of human T-lymphotropic virus type 2 (HTLV-2) supported by a potential new HTLV-2d subtype in Congolese Bambuti Efe Pygmies.

Vandamme AM, Salemi M, Van Brussel M, Liu HF, Van Laethem K, Van Ranst M, Michels L, Desmyter J, Goubau P.

J Virol. 1998 May;72(5):4327-40.

39.

Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain.

Debyser Z, Van Wijngaerden E, Van Laethem K, Beuselinck K, Reynders M, De Clercq E, Desmyter J, Vandamme AM.

AIDS Res Hum Retroviruses. 1998 Mar 20;14(5):453-9.

PMID:
9546805
40.

1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.

Witvrouw M, Arranz ME, Pannecouque C, Declercq R, Jonckheere H, Schmit JC, Vandamme AM, Diaz JA, Ingate ST, Desmyter J, Esnouf R, Van Meervelt L, Vega S, Balzarini J, De Clercq E.

Antimicrob Agents Chemother. 1998 Mar;42(3):618-23.

41.

Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir).

Esté JA, Cabrera C, Schols D, Cherepanov P, Gutierrez A, Witvrouw M, Pannecouque C, Debyser Z, Rando RF, Clotet B, Desmyter J, De Clercq E.

Mol Pharmacol. 1998 Feb;53(2):340-5.

42.

Post-exposure prophylaxis after accidental prion inoculation.

Van Ranst M, Desmyter J.

Lancet. 1998 Feb 21;351(9102):600. No abstract available.

PMID:
9492810
43.

Phylogenetic analysis of a simian T lymphotropic virus type I from a hamadryas baboon.

Liu HF, Goubau P, Van Brussel M, Desmyter J, Vandamme AM.

AIDS Res Hum Retroviruses. 1997 Nov 20;13(17):1545-8. No abstract available.

PMID:
9390755
44.

Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.

Este JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM, Desmyter J, De Clercq E.

Mol Pharmacol. 1997 Jul;52(1):98-104.

45.
46.
47.

Use of a generic polymerase chain reaction assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serology.

Vandamme AM, Van Laethem K, Liu HF, Van Brussel M, Delaporte E, de Castro Costa CM, Fleischer C, Taylor G, Bertazzoni U, Desmyter J, Goubau P.

J Med Virol. 1997 May;52(1):1-7.

PMID:
9131450
48.

Prevalence of hepatitis A, B and C in the Flemish population.

Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Goilav C, Mak R, Muylle L, Pierard D, Stroobant A, Van Loock F, Waumans P, Vranckx R.

Eur J Epidemiol. 1997 Apr;13(3):275-80.

PMID:
9258525
49.
50.

SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.

Witvrouw M, Balzarini J, Pannecouque C, Jhaumeer-Laulloo S, Esté JA, Schols D, Cherepanov P, Schmit JC, Debyser Z, Vandamme AM, Desmyter J, Ramadas SR, de Clercq E.

Antimicrob Agents Chemother. 1997 Feb;41(2):262-8.

Supplemental Content

Loading ...
Support Center